文献速递淋巴瘤

Sonrotoclax单药治疗经抗CD20和BTK抑制剂治疗的套细胞淋巴瘤I/II期研究

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
PubMed 文献 · J Clin Oncol · 2026-07-01

这项全球开放标签I/II期试验评估Sonrotoclax单药在经BTK抑制剂治疗的复发/难治套细胞淋巴瘤患者中的疗效与安全性。125例患者接受160mg或320mg每日一次口服,疗效可评估者103例,独立评审委员会评估的客观缓解率为52.4%,完全缓解率15.5%,中位缓解持续时间15.8个月,中位无进展生存期6.5个月,安全性可控。

要点

  • Sonrotoclax在经BTK抑制剂治疗的R/R MCL中ORR-IRC达52.4%,CR率15.5%。
  • TP53突变亚组仍见缓解,ORR为59.1%。
  • 常见≥3级不良事件为中性粒细胞减少19.1%、血小板减少9.6%、贫血7.8%。

核心结论

  • Sonrotoclax在重度经治的R/R MCL患者中显示快速、持久的缓解和可控的安全性,支持其作为口服疗法的进一步临床评估。

研究设计与样本

  • BGB-11417-201为正在进行的全球、开放标签、I/II期试验(NCT05471843)。
  • Sonrotoclax每日一次口服,经4周逐渐加量至160mg或320mg以减轻肿瘤溶解综合征。
  • 共入组125例患者,接受160mg(n=10)或320mg(n=115)目标剂量。
  • 主要终点为独立评审委员会按Lugano分类评估的客观缓解率;次要终点包括缓解持续时间、无进展生存期、总生存期和安全性。

主要发现

  • 疗效可评估患者(n=103)的ORR-IRC为52.4%(95% CI 42.4-62.4),相比历史对照ORR 30%有统计学显著提高(P<.0001)。
  • 完全缓解率为15.5%。
  • TP53突变患者ORR为59.1%。
  • 中位研究随访14.2个月,中位DOR-IRC为15.8个月,中位PFS-IRC为6.5个月,中位OS未达到。
  • 最常见全等级/≥3级治疗中出现的不良事件为中性粒细胞减少(35.7%/19.1%)、血小板减少(24.3%/9.6%)和贫血(24.3%/7.8%);TLS发生率为7.0%,所有病例均消退无后遗症。

临床怎么用

  • 对于经抗CD20治疗和BTK抑制剂治疗的R/R MCL患者,Sonrotoclax单药可作为潜在口服治疗选择。
  • 用药需采用4周逐渐加量方案以减轻肿瘤溶解综合征风险。
  • 治疗期间需监测中性粒细胞减少、血小板减少和贫血等血液学不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Mantle cell lymphoma (MCL) is a rare and typically aggressive B-cell non-Hodgkin lymphoma characterized by recurrent relapse after short remissions. Sonrotoclax (BGB-11417) is a next-generation B-cell lymphoma 2 inhibitor with greater selectivity and potency than venetoclax, a shorter half-life, and no drug accumulation. Sonrotoclax monotherapy was evaluated in Bruton tyrosine kinase inhibitor-pretreated patients with relapsed/refractory (R/R) MCL. METHODS: BGB-11417-201 (ClinicalTrials.gov identifier: NCT05471843) is an ongoing global, open-label, phase I/II trial. Sonrotoclax was orally administered once daily with gradual, 4-week ramp-up to 160 mg or 320 mg to mitigate tumor lysis syndrome (TLS). The primary end point was overall response rate by the independent review committee (ORR-IRC) per Lugano classification; secondary end points included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Overall, 125 patients were enrolled and assigned to receive sonrotoclax 160 mg (n = 10) or 320 mg (n = 115) target doses once daily. Most patients had advanced disease (stage IV, 78.3%) and were heavily pretreated (median prior therapies, 3). In efficacy-evaluable patients (n = 103), the ORR-IRC was 52.4% (95% CI, 42.4 to 62.4), a statistically significant increase versus the historic control ORR (30%; P < .0001); the complete response rate was 15.5%. Responses were seen across high-risk subgroups, including patients with TP53 mutation (59.1%). With a median study follow-up of 14.2 months, the median DOR-IRC was 15.8 months, and the median PFS-IRC was 6.5 months. Median OS was not reached. The most common all-grade/grade ≥3 treatment-emergent adverse events were neutropenia (35.7%/19.1%), thrombocytopenia (24.3%/9.6%), and anemia (24.3%/7.8%). TLS occurred in 7.0% of patients; all cases resolved without sequelae. CONCLUSION: Sonrotoclax demonstrated rapid, durable responses and manageable safety in heavily pretreated patients with R/R MCL, including high-risk subgroups, supporting its further clinical evaluation as an oral therapy for R/R MCL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Eyre TA, Song Y, Hermine O, et al. Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor. J Clin Oncol. 2026. PMID: 42385124. doi:10.1200/JCO-26-00550

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。